base metals investing Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
base metals investing Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
base metals investing Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
base metals investing Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
base metals investing Mesoblast Acquires Chimeric Antigen Receptor Platform Technology for Precision-Enhanced Cell Products
base metals investing Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
base metals investing Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
base metals investing Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
base metals investing Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
base metals investing Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
SAGA Metals Completes Acquisition of Wolverine Heavy Rare Earth Element Project in Labrador-REE Mineralized Potential Similar to Strange Lake and Tanbreez
Golconda Gold Releases Q2 2026 Production Update at Galaxy And Announces Mobilisation of Mining Contractor at Summit
